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Recessive Mutations in ELOVL4 Cause Ichthyosis,
Intellectual Disability, and Spastic Quadriplegia
Mohammed A. Aldahmesh,1 Jawahir Y. Mohamed,1 Hisham S. Alkuraya,1,2 Ishwar C. Verma,3
Ratna D. Puri,3 Ayodele A. Alaiya,4 William B. Rizzo,5 and Fowzan S. Alkuraya1,6,7,*
Very-long-chain fatty acids (VLCFAs) play important roles in membrane structure and cellular signaling, and their contribution to
human health is increasingly recognized. Fatty acid elongases catalyze the first and rate-limiting step in VLCFA synthesis. Heterozygous
mutations in ELOVL4, the gene encoding one of the elongases, are known to cause macular degeneration in humans and retinal abnor-
malities inmice. However, biallelic ELOVL4mutations have not been observed in humans, andmurinemodels with homozygous muta-
tions die within hours of birth as a result of a defective epidermal water barrier. Here, we report on two human individuals with recessive
ELOVL4mutations revealed by a combination of autozygome analysis and exome sequencing. These individuals exhibit clinical features
of ichthyosis, seizures, mental retardation, and spasticity—a constellation that resembles Sjo¨gren-Larsson syndrome (SLS) but presents
a more severe neurologic phenotype. Our findings identify recessive mutations in ELOVL4 as the cause of a neuro-ichthyotic disease and
emphasize the importance of VLCFA synthesis in brain and cutaneous development.Very-long-chain fatty acids (VLCFAs) with chain length
R24 carbon atoms exist in both saturated and unsaturated
forms; the latter are defined by the presence of one (mono-
unsaturated) or more (polyunsaturated) double bonds.
VLCFAs are largely components of more complex lipids,
such as sphingolipids and phospholipids, that participate
in a wide array of physiological functions. These functions
include nuclear membrane stabilization, cell signaling,
lipid and protein trafficking, modulation of inflammatory
responses through the formation of eicosanoids, myelin
production, normal photoreceptor function, and contribu-
tion to the epidermal water barrier.1–6
VLCFAs are synthesized from shorter fatty acids by the
sequential addition of 2-carbons. The first and rate-limiting
step of this process is a condensation reaction with ma-
lonyl-CoA; this reaction is catalyzed by a family of enzymes
collectively known as fatty acid elongases.7 The diversity
of elongases seems to correlate with the complexity of
organisms. In humans, seven elongases designated as
ELOVL1-7 are known to exist, and these possess different
substrate preferences, tissue expressions, and develop-
mental patterns.8–10
Despite the critical role of elongases in the production of
VLCFAs, the specific contribution of each elongase to
tissue function is unclear. Mutations in only one elongase
gene, ELOVL4 (MIM 605512), are known to cause disease
in humans. Patients with heterozygous ELOVL4mutations
display a juvenile form of macular degeneration known as
Stargardt disease type 3 (STGD3, MIM 600110).11 Interest-
ingly, only three ELOVL4mutations have been reported to
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The Americanpattern, which has experimentally been shown to be
dominant-negative in nature.11–14 These ELOVL4-defi-
cient patients have no apparent phenotype beyond their
macular degeneration, which is probably related to a
deficiency of VLCFA-containing lipids in the retina.15
The phenotypic effects of biallelic ELOVL4 mutations in
humans are not known. However, homozygous Elovl4
knockout in mice results in a lethal cutaneous disease
arising from a defective epidermal water barrier.6
Here, we report on two human individuals with recessive
ELOVL4 mutations who display congenital ichthyosis,
as seen in Elovl4 /mice, along with a profound neurolog-
ical phenotype. This neuro-ichthyotic disease is character-
ized by a constellation of clinical features resembling
Sjo¨gren-Larsson syndrome (SLS) (MIM 270200).16 These
ELOVL4-deficient ‘‘pseudo-SLS’’ individuals provide
researchers with a unique opportunity to study the clinical
effects of severe ELOVL4 deficiency and showcase the
power of exome sequencing, even in simplex cases, to
reveal the genetics of rare Mendelian disorders.
The index person (person 1), now almost 6 years old, was
born to healthy first-cousin Saudi Arabian parents after an
uncomplicated pregnancy. He was born by normal vaginal
delivery at 38 weeks gestation and had a birth weight of
2.81 kg. A collodion membrane covering the skin was
noted immediately after birth, which necessitated admis-
sion to the neonatal intensive-care unit for fluid manage-
ment. The collodion membrane resolved and was replaced
with dry ichthyotic skin. After he was discharged, his
ichthyosis was noted to wax and wane periodically despite
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Figure 1. Clinical Images of Two Individuals with ELOVL4-
Related Pseudo-SLS
(A) A photograph of person 2 shows the hypertonic posture and
ichthyotic skin.
(B) A close-up image of the skin demonstrates the erythematous
ichthyosis and a well-demarcated but less-affected region on the
upper chest.
(C and D) A brain MRI of person 1 (sagittal and coronal views,
respectively) shows delayed myelination and evidence of brain
atrophy.
Figure 2. Autozygome Analysis of Person 1
Blue bars indicate ROH. The locations of ALDH3A2 and ELOVL4
are indicated by red and blue triangles, respectively.Although no body part was fully spared, significant predi-
lection to the neck and diaper areas was noted, and later
the focus shifted to the hands and feet. Profound develop-
mental delay had been evident since early infancy. Recalci-
trant seizures started at the age of 4 months and progres-
sively increased in frequency to approximately one every
1–2 hr, and there was no clear response to antiepileptic
medications. Past medical history is also significant for
recurrent and severe bronchial asthmatic episodes often
requiring hospital admissions. He underwent surgical
repair for bilateral inguinal hernias as an infant. Physical
examination at 5 yr, 10 months of age was notable for
head circumference at the fifth percentile, length <fifth
percentile, and weight at the 25th percentile. He showed
very little interest in his surroundings. No clear dysmor-
phia was noted. His oral exam was significant for gingivitis
and loss of most of his teeth. His skin was remarkably dry,
and scaling was particularly noticeable on his hands and
feet. Severe hypertonia in the upper and lower extremities
was evident, and he was unable to roll over or turn his head
toward his spoken name. He could not bring his hands to
a midline position and was generally immobile. Testicular
size was small. Examination of his chest, heart, and
abdomen was within normal limits. Ophthalmologic
examination was limited by a lack of cooperation and
parental refusal to sedate the patient. Nevertheless, the
macula could be visualized and had a normal appearance.
Limited electroretinograms (ERGs) revealed a normal746 The American Journal of Human Genetics 89, 745–750, Decembflicker response. High myopia (11 D) was diagnosed,
and amblyopia was also suspected. Interestingly, although
the mother’s eye examination was completely normal, the
father’s eye examination revealed some drusen-like flecks
in the macula and moderate myopia.
Laboratory investigations included a normal karyotype
and normal plasma acylcarnitines and amino acids, liver
function tests, electrolytes, thyroid function tests, blood
lactate, ammonia, and urine organic acids. Brain magnetic
resonance imaging (MRI) was performed at 6 months of
age and revealed severely delayed myelination and evi-
dence of brain atrophy (Figure 1). The combination of
ichthyosis, intellectual disability, and spastic quadriplegia
in person 1 raised the possibility of SLS,16 so biochemical
analysis of fibroblast fatty aldehyde dehydrogenase
(FALDH) activity was pursued because FALDH deficiency
is the hallmark of SLS.17 However, FALDH activity was
found to be normal, which suggested that person 1 had
‘‘pseudo-SLS.’’ Therefore, we enrolled him in a study
approved by the institutional review board of the King
Faisal Specialist Hospital and Research Center. Our
hypothesis was that, in view of parental consanguinity,
his condition was caused by autozygosity for an ancestral
haplotype that harbors an autosomal-recessive mutation.18
A QIAGEN kit was used for extracting genomic DNA
from EDTA-treated whole blood from the index patient
and his two parents. Genotyping was performed with the
Axiom platform (Affymetrix), and autozygome analysis
was run on autoSNPs as previously described.19 Several
runs of homozygosity (ROH, cutoff 2 Mb) that were not
shared by the parents were evident (Figure 2 and Table
S1). Because ALDH3A2 (MIM 609523), the only known
gene mutated in SLS, was present in one ROH, it was
sequenced both at the genomic and cDNA levels as
described,17 but no mutation was identified. Therefore,
we proceeded with the sequencing of patient 1’s exome
at 303 coverage by using Illumina’s HiSeq 2000 platform.
Figure 3 summarizes the filtration strategy used in this
study. We used dbSNP132 and the 1000 Genomes Project
to highlight novel variants. We also used 72 in-house Saudi
exomes to exclude variants, even when present once in theer 9, 2011
Figure 3. FilteringStrategyUsed for Identification of aCausative
Recessive Mutation in a Simplex Case with Pseudo-SLSheterozygous state, because we reasoned that a 1/144 allele
frequency is too high for a disease this rare. We have
previously demonstrated the efficiency of using the auto-
zygome as a filter of the variants generated by exome
sequencing.20,21 Indeed, by applying the autozygome
among other filters (PolyPhen for the probability of patho-
genicity and Tissue-specific Gene Expression and Regula-
tion [TiGER] and UniGene expression databases for skin
expression), we narrowed the search to just three novel
coding variants: TBCC (MIM 602971)(NM_003192.2:
c.258G>T [p.Glu86Asp]), ELOVL4 (NM_022726.2:
c.646C>T [p.Arg216X]), and TIAM1 (MIM 600687)
(NM_003253.2:c.3020G>A [p.Arg1007His]) (Figures 3
and 4 and Table S2). Of these, the truncating nonsense
mutation in exon 5 of ELOVL4 was the most plausible
candidate for causing the disease phenotype. This muta-
tion was identified in 86 reads, which suggested high reli-
ability of the call. Indeed, Sanger sequencing confirmed
the homoallelic state of this mutation in the patient and
the carrier state of the parents, and a screen of 192 Saudi
controls was negative.
In view of this finding, we screened 15 additional
pseudo-SLS individuals (defined as having an SLS pheno-
type with normal FALDH activity) for ELOVL4 mutations
using Sanger sequencing (primer sequences and PCR
conditions for ELOVL4 are shown in Table S3). These indi-
viduals were recruited by one of the authors (W.B.R.) as
part of an IRB-approved protocol at the University of
Nebraska Medical Center. All had ichthyosis, psychomotor
retardation, and spasticity, along with normal fibroblastThe AmericanFALDH activity and/or sequencing of ALDH3A2. One
individual was found to harbor a novel homozygous
truncating mutation in exon 6 of ELOVL4 (c.690del
[p.Ile230Metfs*22]) (Figure 4). DNA analysis of the person’s
parents showed that they were heterozygous for this
mutation.
This person (person 2) was born at 35 weeks gestation to
consanguineous Asian Indian parents. He was noted to
have dry skin shortly after birth but exhibited no collodion
membrane. At 2 months of age, myoclonic seizures began,
and he had profound motor delay over the ensuing first
year. He underwent surgery for a left-sided inguinal hernia.
At 11 months of age, physical examination showed a
height of 63 cm (<third percentile), a weight of 4.5 kg
(<third percentile), and a head circumference of 40 cm
(<third percentile). There were no dysmorphic features.
His hair and nails appeared normal. No teeth had erupted.
The ophthalmologic exam showed no cataract or macular
abnormalities, but he did have temporal pallor in both
eyes and exhibited photophobia. The skin had generalized
erythematous ichthyosis with fine scales over most of the
body but sparing the face (Figure 1). There were well-
demarcated regions of skin that appeared less erythema-
tous and hyperkeratotic. The neurologic exam showed
increased tone in all four limbs and scissoring and contrac-
tures of the lower extremities.
An EEG showed bilateral posterior and generalized
epileptogenic activity consistent with myoclonic epilepsy.
Studies showed abnormal visual evoked potentials. No
fibroblasts were available for study. Person 2 was bedridden
and never gained the ability to sit, speak, or feed himself.
He died from aspiration at 2 years of age. A similarly
affected sibling died at 6 months of age.
The identification of ELOVL4mutations in patients with
the atypical juvenile form of macular degeneration
(SGDT3) sparked interest in the role of VLCFAs in the
physiology of the retina.22,23 Using several mouse models
in which the heterozygous-dominant SGDT3 mutation
was introduced by genetic knockin made it possible to
recapitulate a retinal phenotype and confirm the defi-
ciency of phosphatidylcholine-containing fatty acids >28
carbons long.24 Interestingly, this finding was true both
in heterozygous mice carrying the human dominant
SGDT3 5 bp deletion as well as homozygous-knockout
mice with a null allele. However, mice heterozygous for
the null allele appeared to have no phenotypic conse-
quences, suggesting that the heterozygous 5 bp deletion
in humans is a dominant-negative mutation.25 This
discovery is further supported by functional studies that
convincingly showed that the mutant ELOVL4 failed to
be targeted to the endoplasmic reticulum and caused mis-
localization of the wild-type protein.26–29 The loss of the
ER targeting signal in the C terminus of ELOVL4, which
characterizes all three dominant mutations reported in
humans, is a likely explanation of this observation. We
ruled out nonsense-mediated decay as a result of the trun-
cating mutation in fibroblasts from person 1 (Figure S1),Journal of Human Genetics 89, 745–750, December 9, 2011 747
Figure 4. Cartoon of ELOVL4
Five transmembrane (TM) domains are indicated by boxes 1–5. The diiron-oxo binding motif (His158-His162) is circled, and Carboxy-
terminal dilysine is columned. The previously reported mutations are shown on top of the cartoon, and the two mutations in this work
with the DNA chromatogram are shown below the cartoon in the TM-4 domain.so it seemed likely that a truncated version of ELOVL4 was
being made by this individual. However, immunoblot
analysis of his cells consistently showed that he produced
normal-sized ELOVL4, albeit at about a 45% reduced level
(Figure S2). This is surprising because his nonsense muta-
tion predicted a 24 kDa protein compared to the normal
37 kDa ELOVL4. We considered the possibility that this
might represent a nonspecific 37 kDa band, but two inde-
pendent anti-ELOVL4 antibodies gave the exact same
result. The possibility that this protein was a product of
an alternatively spliced transcript that skipped exon 5
and did not contain the mutation was not supported by
RT-PCR analysis, which failed to identify any RNA tran-
script other than the mutant RNA that harbored the
nonsense mutation (Figure S1). Therefore, we were left
with the possibility of a nonsense readthrough. Such read-
throughs have previously been detected under experi-
mental conditions such as aminoglycoside treatment,
suppressor tRNA, and depletion of eRF1 and eRF3. We
did a 2D gel electrophoresis to examine the effect of the
presumed readthrough on the protein, and other than
the difference in abundance, there was no apparent differ-
ence in charge (Figure S3). It is not known whether the
apparent nonsense readthrough is seen in keratinocytes
and neural cells, which are probably more directly respon-
sible for the cutaneous and neurologic phenotypes. Thus,
it remains unclear whether the mutational mechanism in
person 1 is mediated by a defective or deficient ELOVL4.
Given that person 2 has a similar phenotype and harbors
a homozygous frameshift mutation, it is possible that the
overall mutational mechanism is loss of function.
The cutaneous phenotype of the two affected children
is comparable to that of homozygous mouse models of
Elovl4 mutations. These mice die within hours after birth
as a result of severe ichthyosis, disruption of the epidermal
water barrier, and consequent dehydration.25 Consistent
with the role of ELOVL4 in VLCFA synthesis and its local-
ization in skin, the epidermis of these mice completely748 The American Journal of Human Genetics 89, 745–750, Decemblacks acylceramide, an essential VLCFA-containing compo-
nent of the water barrier.25 The apparent lack of a cuta-
neous phenotype in heterozygous mice therefore suggests
that the retinal phenotype is more sensitive to ELOVL4
dosage than is the epidermal phenotype.
In addition to the ichthyosis phenotype, the study indi-
viduals have suffered from severe brain damage likely
caused by a deficiency of VLCFAs that are >28 carbons
long, which are essential components of the sphingolipids
that make up 30% of the myelin sheath of the brain.30
Unfortunately, early lethality of the homozygous mouse
model precludes observation of a comparable neurologic
phenotype.
We are intrigued by the apparent lack of a macular
phenotype in person 1. Obviously, we cannot fully rule
out the presence of a macular phenotype given the limited
eye exam, including our inability to perform a full ERG or
more detailed optical coherence tomography. However,
the lack of macular flecks indicative of lipofuscin accumu-
lation, which is typical of STGD3, might be explained by
his young age. We also note that despite the recessive
nature of person 1’s mutation, the very mild macular
changes in the father might be related to his heavy
smoking habit. Several studies have shown the interaction
between smoking as an environmental factor and the
genetic predisposition to macular degeneration.31,32 It
would be of interest to observe the father’s macula over
time after smoking cessation, which he promised to
consider after the revelation of his carrier status.
Although much remains to be learned about the
biochemical changes in ELOVL4-deficient individuals,
the deficiency in VLCFA synthesis suggests a therapeutic
approach to repletion of these fatty acids. The parents of
person 1 have independently tried to bypass the metabolic
defect in their child by administering oral fish oil supple-
ments, and we also recommended ceramide-based skin
lotions. Whether this intervention will modify the natural
history of the disease remains unknown. Feeding theer 9, 2011
patient a diet enriched with VLCFAs, i.e., supplementation
with peanut oil, seems a rational approach, but entry of
these exogenous fatty acids into the brain is less likely.
On the other hand, topical application of VLCFAs to the
skin might be considered as a potential therapy for the
ichthyosis.
In summary, we show the power of combining homozy-
gosity mapping with next-generation sequencing for
identifying the cause of autosomal-recessive diseases
even in simplex cases.18,20 Our findings highlight the
critical role of ELOVL4 and VLCFAs in early brain develop-
ment and in the integrity of the epidermal water barrier.Supplemental Data
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